Global and United States End Stage Renal Disease (ESRD) Therapy Market Report & Forecast 2022-2028

Table of Contents

1 Study Coverage

• 1.1 End Stage Renal Disease (ESRD) Therapy Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) & (US$ Million) Introduction
• 1.2 Global End Stage Renal Disease (ESRD) Therapy Outlook 2017 VS 2022 VS 2028
  • 1.2.1 Global End Stage Renal Disease (ESRD) Therapy Market Size for the Year 2017-2028
  • 1.2.2 Global End Stage Renal Disease (ESRD) Therapy Market Size for the Year 2017-2028
• 1.3 End Stage Renal Disease (ESRD) Therapy Market Size, United States VS Global, 2017 VS 2022 VS 2028
  • 1.3.1 The Market Share of United States End Stage Renal Disease (ESRD) Therapy in Global, 2017 VS 2022 VS 2028
  • 1.3.2 The Growth Rate of End Stage Renal Disease (ESRD) Therapy Market Size, United States VS Global, 2017 VS 2022 VS 2028
• 1.4 End Stage Renal Disease (ESRD) Therapy Market Dynamics
  • 1.4.1 End Stage Renal Disease (ESRD) Therapy Industry Trends
  • 1.4.2 End Stage Renal Disease (ESRD) Therapy Market Drivers
  • 1.4.3 End Stage Renal Disease (ESRD) Therapy Market Challenges
  • 1.4.4 End Stage Renal Disease (ESRD) Therapy Market Restraints
• 1.5 Study Objectives
• 1.6 Years Considered

2 End Stage Renal Disease (ESRD) Therapy by Type

• 2.1 End Stage Renal Disease (ESRD) Therapy Market Segment by Type
  • 2.1.1 Hemodialysis
  • 2.1.2 Peritoneal Dialysis
  • 2.1.3 Kidney Transplantation
• 2.2 Global End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017, 2022 & 2028)
• 2.3 Global End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2028)
• 2.4 United States End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017, 2022 & 2028)
• 2.5 United States End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2028)

3 End Stage Renal Disease (ESRD) Therapy by Application

• 3.1 End Stage Renal Disease (ESRD) Therapy Market Segment by Application
  • 3.1.1 Hospitals
  • 3.1.2 Kidney Dialysis Centers
  • 3.1.3 At Homes
  • 3.1.4 Others
• 3.2 Global End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017, 2022 & 2028)
• 3.3 Global End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2028)
• 3.4 United States End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017, 2022 & 2028)
• 3.5 United States End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2028)

4 Global End Stage Renal Disease (ESRD) Therapy Competitor Landscape by Company

• 4.1 Global End Stage Renal Disease (ESRD) Therapy Market Size by Company
  • 4.1.1 Top Global End Stage Renal Disease (ESRD) Therapy Companies Ranked by Revenue (2021)
  • 4.1.2 Global End Stage Renal Disease (ESRD) Therapy Revenue by Player (2017-2022)
• 4.2 Global End Stage Renal Disease (ESRD) Therapy Concentration Ratio (CR)
  • 4.2.1 End Stage Renal Disease (ESRD) Therapy Market Concentration Ratio (CR) (2017-2022)
  • 4.2.2 Global Top 5 and Top 10 Largest Companies of End Stage Renal Disease (ESRD) Therapy in 2021
  • 4.2.3 Global End Stage Renal Disease (ESRD) Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 4.3 Global End Stage Renal Disease (ESRD) Therapy Headquarters, Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) & (US$ Million) Type
  • 4.3.1 Global End Stage Renal Disease (ESRD) Therapy Headquarters and Area Served
  • 4.3.2 Global End Stage Renal Disease (ESRD) Therapy Companies Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) & (US$ Million) Type
  • 4.3.3 Date of International Companies Enter into End Stage Renal Disease (ESRD) Therapy Market
• 4.4 Companies Mergers & Acquisitions, Expansion Plans
• 4.5 United States End Stage Renal Disease (ESRD) Therapy Market Size by Company
  • 4.5.1 Top End Stage Renal Disease (ESRD) Therapy Players in United States, Ranked by Revenue (2021)
  • 4.5.2 United States End Stage Renal Disease (ESRD) Therapy Revenue by Players (2020, 2021 & 2022)

5 Global End Stage Renal Disease (ESRD) Therapy Market Size by Region

• 5.1 Global End Stage Renal Disease (ESRD) Therapy Market Size by Region: 2017 VS 2022 VS 2028
• 5.2 Global End Stage Renal Disease (ESRD) Therapy Market Size by Region (2017-2028)
  • 5.2.1 Global End Stage Renal Disease (ESRD) Therapy Market Size by Region: 2017-2022
  • 5.2.2 Global End Stage Renal Disease (ESRD) Therapy Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level

• 6.1 North America
  • 6.1.1 North America End Stage Renal Disease (ESRD) Therapy Market Size YoY Growth 2017-2028
  • 6.1.2 North America End Stage Renal Disease (ESRD) Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.1.3 United States
  • 6.1.4 Canada
• 6.2 Asia-Pacific
  • 6.2.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size YoY Growth 2017-2028
  • 6.2.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Facts & Figures by Region (2017, 2022 & 2028)
  • 6.2.3 China
  • 6.2.4 Japan
  • 6.2.5 South Korea
  • 6.2.6 India
  • 6.2.7 Australia
  • 6.2.8 China Taiwan
  • 6.2.9 Indonesia
  • 6.2.10 Thailand
  • 6.2.11 Malaysia
• 6.3 Europe
  • 6.3.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size YoY Growth 2017-2028
  • 6.3.2 Europe End Stage Renal Disease (ESRD) Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.3.3 Germany
  • 6.3.4 France
  • 6.3.5 U.K.
  • 6.3.6 Italy
  • 6.3.7 Russia
• 6.4 Latin America
  • 6.4.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size YoY Growth 2017-2028
  • 6.4.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.4.3 Mexico
  • 6.4.4 Brazil
  • 6.4.5 Argentina
• 6.5 Middle East and Africa
  • 6.5.1 Middle East and Africa End Stage Renal Disease (ESRD) Therapy Market Size YoY Growth 2017-2028
  • 6.5.2 Middle East and Africa End Stage Renal Disease (ESRD) Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.5.3 Turkey
  • 6.5.4 Saudi Arabia
  • 6.5.5 UAE

7 Company Profiles

• 7.1 Fresenius
  • 7.1.1 Fresenius Company Details
  • 7.1.2 Fresenius Business Overview
  • 7.1.3 Fresenius End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.1.4 Fresenius Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.1.5 Fresenius Recent Development
• 7.2 DaVita
  • 7.2.1 DaVita Company Details
  • 7.2.2 DaVita Business Overview
  • 7.2.3 DaVita End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.2.4 DaVita Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.2.5 DaVita Recent Development
• 7.3 Baxter
  • 7.3.1 Baxter Company Details
  • 7.3.2 Baxter Business Overview
  • 7.3.3 Baxter End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.3.4 Baxter Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.3.5 Baxter Recent Development
• 7.4 Nipro
  • 7.4.1 Nipro Company Details
  • 7.4.2 Nipro Business Overview
  • 7.4.3 Nipro End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.4.4 Nipro Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.4.5 Nipro Recent Development
• 7.5 B. Braun
  • 7.5.1 B. Braun Company Details
  • 7.5.2 B. Braun Business Overview
  • 7.5.3 B. Braun End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.5.4 B. Braun Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.5.5 B. Braun Recent Development
• 7.6 Asahi Kasei
  • 7.6.1 Asahi Kasei Company Details
  • 7.6.2 Asahi Kasei Business Overview
  • 7.6.3 Asahi Kasei End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.6.4 Asahi Kasei Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.6.5 Asahi Kasei Recent Development
• 7.7 Nikkiso
  • 7.7.1 Nikkiso Company Details
  • 7.7.2 Nikkiso Business Overview
  • 7.7.3 Nikkiso End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.7.4 Nikkiso Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.7.5 Nikkiso Recent Development
• 7.8 WEGO
  • 7.8.1 WEGO Company Details
  • 7.8.2 WEGO Business Overview
  • 7.8.3 WEGO End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.8.4 WEGO Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.8.5 WEGO Recent Development
• 7.9 Newsol
  • 7.9.1 Newsol Company Details
  • 7.9.2 Newsol Business Overview
  • 7.9.3 Newsol End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.9.4 Newsol Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.9.5 Newsol Recent Development
• 7.10 Mayo Clinic
  • 7.10.1 Mayo Clinic Company Details
  • 7.10.2 Mayo Clinic Business Overview
  • 7.10.3 Mayo Clinic End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.10.4 Mayo Clinic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.10.5 Mayo Clinic Recent Development
• 7.11 Guangdong Biolight
  • 7.11.1 Guangdong Biolight Company Details
  • 7.11.2 Guangdong Biolight Business Overview
  • 7.11.3 Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.11.4 Guangdong Biolight Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.11.5 Guangdong Biolight Recent Development
• 7.12 Medtronic
  • 7.12.1 Medtronic Company Details
  • 7.12.2 Medtronic Business Overview
  • 7.12.3 Medtronic End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.12.4 Medtronic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.12.5 Medtronic Recent Development
• 7.13 Sanxin Medtec
  • 7.13.1 Sanxin Medtec Company Details
  • 7.13.2 Sanxin Medtec Business Overview
  • 7.13.3 Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.13.4 Sanxin Medtec Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.13.5 Sanxin Medtec Recent Development
• 7.14 Jafron Biomedical
  • 7.14.1 Jafron Biomedical Company Details
  • 7.14.2 Jafron Biomedical Business Overview
  • 7.14.3 Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.14.4 Jafron Biomedical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.14.5 Jafron Biomedical Recent Development
• 7.15 SWS Hemodialysis Care
  • 7.15.1 SWS Hemodialysis Care Company Details
  • 7.15.2 SWS Hemodialysis Care Business Overview
  • 7.15.3 SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.15.4 SWS Hemodialysis Care Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.15.5 SWS Hemodialysis Care Recent Development
• 7.16 Tianyi Medical
  • 7.16.1 Tianyi Medical Company Details
  • 7.16.2 Tianyi Medical Business Overview
  • 7.16.3 Tianyi Medical End Stage Renal Disease (ESRD) Therapy Introduction
  • 7.16.4 Tianyi Medical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
  • 7.16.5 Tianyi Medical Recent Development

8 Research Findings and Conclusion

9 Appendix

• 9.1 Research Methodology
  • 9.1.1 Methodology/Research Approach
  • 9.1.2 Data Source
• 9.2 Author Details